Tokyo, Japan

Kosuke Funayama

This inventor holds 1 USPTO granted patent. Top assignee: Taisho Pharmaceutical Co., Ltd.. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kosuke Funayama. Retrieved from https://idiyas.com/inventor/kosuke-funayama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kosuke Funayama - Innovator in Pharmaceutical Chemistry

Introduction

Kosuke Funayama is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with therapeutic potential.

Latest Patents

Funayama holds a patent for a pyridine compound substituted with azole. This invention provides a compound represented by a specific formula that exhibits an inhibitory effect on the 20-HETE producing enzyme. The compound's structure includes various substituents that enhance its pharmacological properties.

Career Highlights

Funayama is associated with Taisho Pharmaceutical Co., Ltd., where he has been instrumental in advancing research and development efforts. His work focuses on creating innovative solutions to address medical needs.

Collaborations

He collaborates with talented colleagues, including Hiroaki Tanaka and Madoka Kawamura, to drive forward the research initiatives at his company.

Conclusion

Kosuke Funayama's contributions to pharmaceutical chemistry highlight his role as an innovator in the industry. His patent for a pyridine compound demonstrates his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…